Report : South and Central America Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Bioreactor, Lyophilization, Electrospinning, Control flow Centrifugation, Ultrasonic Lysis, Genome Editing Technology, Cell Immortalization Technology, and Viral Vector Technology); Cell Type (Stem Cell, Immune Cell, Human Embryonic Stem Cell, Pluripotent Stem Cell, and Hematopoietic Stem Cells), Indication (Cardiovascular Disease (CVD), Oncology, Wound Healing, Orthopaedic, and Others); End User (Hospitals and Clinics, Diagnostic Centres, Regenerative Medicine Centres, and Academic and Research Institute)
Bioreactor Segment has the Largest Share of Technology in the South and Central America Cell Therapy Bioprocessing Market during 2021–2028
According to a new market research study on “South and Central America Cell Therapy Bioprocessing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Cell Type, Indication, and End User” is expected to reach US$ 994.7 million by 2028 from US$ 458.2 million in 2021. The market is estimated to grow at a CAGR of 11.7% from 2021 to 2028. The report provides trends prevailing in the South and Central America Cell therapy bioprocessing market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the challenges such as high cost of product, regulatory challenges, and logistics challenges.
COVID-19 cases are increasing in South and Central America. With the outbreak of the second wave of COVID-19, the number of cases in SCAM countries has increased. Despite this impact, the region's biotechnology industry is doing little to fight the virus, and the lack of projects has exposed the sector's vulnerability. There are a few unrelated and autonomous projects going on, but they are happening independently of one another, meaning that there is no strong biotech network. Currently, Brazil has the second highest reported cases of COVID-19 infection across the world. Brazilian Association of Hematology, Hemotherapy and Cellular Therapy have constituted a panel of experts to carefully examine and review the use of cellular therapies for the treatment of COVID 19. Such an initiatives will bring significant growth for cell therapy bioprocessing market in long run.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, in 2020, the bioreactor segment accounted for the cell therapy bioprocessing market's most significant market share. The segment's growth is expected due to its utilization for making cells and scaling up the volume for cellular products. Bioreactors are the primary equipment required during the cell therapy bioprocessing thus are expected to continue their dominancy during the forecast period. However, the genome-editing technology segment is expected to grow at the fastest CAGR. Genome editing technology is widely used for targeting and designing the cellular and genes for cell therapies.
Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc are among the leading companies in the South and Central America cell therapy bioprocessing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2021, Sartorius Partners with RoosterBio. The partnership seeks to drive the scale-up of hMSC production for regenerative medicine by exploiting both companies' best-in-class solutions to dramatically minimise process development efforts, industrialise the supply chain, and accelerate the growth and commercialization of game-changing cell-based regenerative cures.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, the Cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Based on cell type, the cell therapy bioprocessing market is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, and hematopoietic stem cells. Based on indication, the cell therapy bioprocessing market is segmented into cardiovascular disease (cvd), oncology, wound healing, orthopaedic, and others. Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centres, regenerative medicine centres, and academic and research institute. Geographically, the cell therapy bioprocessing market is segmented into South and Central America (Brazil, Argentina, Rest of South and Central America).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com